EVOLENT HEALTH ($EVH) posted quarterly earnings results for Q4 2025 on Tuesday, February 24th. The company reported earnings of $0.08 per share, beating estimates of $0.06 by $0.02. The company also reported revenue of $468,720,000, missing estimates of $473,502,877 by $-4,782,877.
Stock price change since market close: -1.25%
You can see Quiver Quantitative's $EVH stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
EVOLENT HEALTH Insider Trading Activity
EVOLENT HEALTH insiders have traded $EVH stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $EVH stock by insiders over the last 6 months:
- BRENDAN B SPRINGSTUBB purchased 10,000 shares for an estimated $38,199
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
EVOLENT HEALTH Hedge Fund Activity
We have seen 121 institutional investors add shares of EVOLENT HEALTH stock to their portfolio, and 149 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 8,735,926 shares (-99.8%) from their portfolio in Q4 2025, for an estimated $34,943,704
- DURABLE CAPITAL PARTNERS LP removed 6,423,293 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $54,341,058
- EVENTIDE ASSET MANAGEMENT, LLC removed 6,292,511 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $25,170,044
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC removed 4,035,475 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $16,141,900
- UBS GROUP AG added 2,707,210 shares (+79.6%) to their portfolio in Q4 2025, for an estimated $10,828,840
- D. E. SHAW & CO., INC. added 2,531,506 shares (+92.5%) to their portfolio in Q4 2025, for an estimated $10,126,024
- VANGUARD GROUP INC removed 2,052,765 shares (-18.7%) from their portfolio in Q4 2025, for an estimated $8,211,060
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
EVOLENT HEALTH Analyst Ratings
Wall Street analysts have issued reports on $EVH in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 11/21/2025
- JP Morgan issued a "Overweight" rating on 11/17/2025
- Canaccord Genuity issued a "Buy" rating on 11/14/2025
- BMO Capital issued a "Outperform" rating on 11/13/2025
- Citizens issued a "Market Outperform" rating on 11/10/2025
- Truist Securities issued a "Buy" rating on 11/10/2025
- BTIG issued a "Buy" rating on 11/07/2025
To track analyst ratings and price targets for EVOLENT HEALTH, check out Quiver Quantitative's $EVH forecast page.
EVOLENT HEALTH Price Targets
Multiple analysts have issued price targets for $EVH recently. We have seen 9 analysts offer price targets for $EVH in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- David Larsen from BTIG set a target price of $10.0 on 02/02/2026
- Daniel Grosslight from Citigroup set a target price of $6.0 on 01/09/2026
- Constantine Davides from Citizens set a target price of $10.0 on 01/06/2026
- Anne Samuel from JP Morgan set a target price of $7.0 on 11/17/2025
- Richard Close from Canaccord Genuity set a target price of $9.0 on 11/14/2025
- Sean Dodge from BMO Capital set a target price of $7.0 on 11/13/2025
- Michael Wiederhorn from Oppenheimer set a target price of $12.0 on 11/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
